the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets
PhoreMost has raised €39M across 1 funding round from 8 investors, most recently a Series B round in Sep 2024. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-09-11 | Series B | €39M |
| Astellas Venture Management,BGF,Jonathan Milner,Morningside Ventures,o2h Ventures,Parkwalk Advisors+2 more |
| View deal → |
